National and Kapodistrian University of Athens
Ο ρόλος της αναστολής του πρωτεασώματος στη λειτουργία των αγγείων και στην αθηρωμάτωση σε ανθρώπους
Abstract
dc:descriptionCarfilzomib (CFZ) improves survival in relapsed/refractory multiple myeloma (RRMM) but is associated with cardiovascular adverse events (CVAE). Although experimental data suggest that CFZ associated cardiovascular toxicity is exerted at least in part through endothelial dysfunction, the clinical relevance of the latter as a toxicity biomarker in CFZ treatment in humans was not investigated in depth at the time of the design, development and publication of the results of the present thesis. We prospectively investigated the effect of CFZ on endothelial function and hemodynamic parameters as wells as associations with CVAE in patients with RRMM. Forty-eight patients treated with Kd (CFZ 20/56 mg/m2 and dexamethasone) underwent serial endothelial function evaluation, using brachial artery flow-mediated dilatation (FMD), the most well-established clinical marker for assessing endothelial function in peripheral arterial conduits, and 26S proteasome activity (PrA) measurement in PBMCs; patients were followed until disease progression or cycle 6 for a median of 10 months. FMD decreased acutely after the 1st dose (baseline FMD(%) mean±SD 5.44±3.74 and 2 hours post CFZ infusion 3.51±2.77, p=0.008). Likewise, PrA measured in PBMCsdecreased acutely after the 1st CFZ dose (2.50±1.48, and 2 hours post CFZ 0.350±0.248, p<0.001). Also, FMD decreased at cycles 3 and 6 compared to baseline (p≤0.05). FMD changes were associated with CFZ induced PrA changes (p<0.05) and lower PrA recovery during 1st cycle was associated with more prominent FMD decrease (p=0.034 for group interaction). During treatment, 25 patients developed Grade≥3 CVAE. Low baseline FMD (HR 2.57 lowest vs. higher tertiles, 95%CI 1.081-6.1) was an independent predictor of CVAE. During treatment, an acute FMD decrease>40% at the end of 1st cycle was also independently associated with CVAEs (HR=3.91, 95%CI 1.29-11.83). With regard to hemodynamic parameters, there is an overall trend towards a reduction in peripheral and central blood pressure both acutely and in the long-term during carfilzomib treatment. A correlation with proteasome activity is observed, as patients with adequate recovery of the proteasome show greater blood pressure reduction. Kd treatment impairs endothelial function which is associated with PrA inhibition and recovery. Both pre- and post-treatment FMD predicted CFZ-related CVAEs supporting its role as a possible cardiovascular toxicity biomarker.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Laina, Ageliki
- Λαϊνά, Αγγελική
Subjects
dc:subject × 18- Πρωτεάσωμα
- Καρφιλζομίμπη
- Ενδοθηλιακή δυσλειτουργία
- Καρδιαγγειακή τοξικότητα
- Proteasome
- Carfilzomib
- Endothelial dysfunction
- Cardiovascular toxicity
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Καρδιολογία και Καρδιοαγγειακά νοσήματα
- Βασική Ιατρική
- Μοριακή ιατρική
- Clinical Medicine
- Medical and Health Sciences
- Cardiology and Cardiovascular Medicine
- Basic Medicine
- Molecular Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60089